Disc Medicine, Inc. Interest Expense Nonoperating
Disc Medicine, Inc. (IRON) reported Interest Expense Nonoperating of $908.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- Disc Medicine, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $908.00K, a 0.22% decline year-over-year.
- Disc Medicine, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $844.00K, a 5.91% decline year-over-year.
- Disc Medicine, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $883.00K, a 54.37% increase year-over-year.
- Disc Medicine, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $917.00K.
- Disc Medicine, Inc. interest expense nonoperating for fiscal 2025 was $3.61M, a 530.59% increase from fiscal 2024.
- Disc Medicine, Inc. interest expense nonoperating for fiscal 2024 was $572.00K.
- Disc Medicine, Inc. interest expense nonoperating for fiscal 2023 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $908.00K 10-Q · filed 2026-07-30 | $1.75M 10-Q · filed 2026-07-30 | $2.63M derived: sum of 3 quarters · filed 2026-07-30 | $3.55M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $844.00K 10-Q · filed 2026-05-05 | $1.73M derived: sum of 2 quarters · filed 2026-05-05 | $2.64M derived: sum of 3 quarters · filed 2026-05-05 | $3.55M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $883.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.80M derived: sum of 2 quarters · filed 2026-02-26 | $2.71M derived: sum of 3 quarters · filed 2026-07-30 | $3.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $917.00K 10-Q · filed 2025-11-06 | $1.83M derived: sum of 2 quarters · filed 2026-07-30 | $2.72M 10-Q · filed 2025-11-06 | $3.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $910.00K 10-Q · filed 2026-07-30 | $1.81M 10-Q · filed 2026-07-30 | $2.38M derived: sum of 3 quarters · filed 2026-07-30 | $2.38M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $897.00K 10-Q · filed 2026-05-05 | $1.47M derived: sum of 2 quarters · filed 2026-05-05 | $1.47M derived: sum of 3 quarters · filed 2026-05-05 | $1.47M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $572.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $572.00K derived: sum of 2 quarters · filed 2026-02-26 | $572.00K derived: sum of 3 quarters · filed 2026-02-26 | $572.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |